Vitamin D binding protein macrophage-activating factor

Drug Profile

Vitamin D binding protein macrophage-activating factor

Alternative Names: EF-022; GcMAF; Globulin component macrophage activating factor

Latest Information Update: 29 Aug 2016

Price : $50

At a glance

  • Originator Einstein Medical Center
  • Developer Efranat; Socrates Institute for Therapeutic Immunology
  • Class Antineoplastics; Carrier proteins; Lymphokines
  • Mechanism of Action Macrophage activating factor replacements; Macrophage stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Recurrent respiratory papillomatosis
  • No development reported Breast cancer; Colorectal cancer; Prostate cancer

Most Recent Events

  • 02 Aug 2016 Efranat plans a phase I trial for Recurrent respiratory papillomatosis in Israel (SC and IM) (NCT02854761)
  • 01 Aug 2016 Preclinical trials in Recurrent respiratory papillomatosis in Israel (Parenteral) before August 2016
  • 01 May 2014 Phase-I clinical trials in Solid tumours (Inoperable/Unresectable, Recurrent, Metastatic disease) in Israel (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top